These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38969753)

  • 1. Aticaprant, a kappa opioid receptor antagonist, and the recovered 'interest and pleasure' in the concept of major depressive disorder.
    Demyttenaere K
    Eur Arch Psychiatry Clin Neurosci; 2024 Jul; ():. PubMed ID: 38969753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.
    Schmidt ME; Kezic I; Popova V; Melkote R; Van Der Ark P; Pemberton DJ; Mareels G; Canuso CM; Fava M; Drevets WC
    Neuropsychopharmacology; 2024 Aug; 49(9):1437-1447. PubMed ID: 38649428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice.
    Jacobson ML; Wulf HA; Browne CA; Lucki I
    Psychopharmacology (Berl); 2020 Dec; 237(12):3715-3728. PubMed ID: 32894343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aticaprant (Clinically Developed Kappa-Opioid Receptor Antagonist) Combined With Naltrexone Prevents Alcohol "Relapse" Drinking.
    Zhou Y; Zhou DC; Kreek MJ
    J Pharm Pharmacol (Los Angel); 2022 May; 9(1):. PubMed ID: 35832748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder.
    Hampsey E; Jelen L; Young AH
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):193-204. PubMed ID: 38682267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
    Krystal AD; Pizzagalli DA; Smoski M; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu D; Murrough JW; Yang H; Weiner RD; Calabrese JR; Sanacora G; Hermes G; Keefe RSE; Song A; Goodman W; Szabo ST; Whitton AE; Gao K; Potter WZ
    Nat Med; 2020 May; 26(5):760-768. PubMed ID: 32231295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
    Costi S; Morris LS; Kirkwood KA; Hoch M; Corniquel M; Vo-Le B; Iqbal T; Chadha N; Pizzagalli DA; Whitton A; Bevilacqua L; Jha MK; Ursu S; Swann AC; Collins KA; Salas R; Bagiella E; Parides MK; Stern ER; Iosifescu DV; Han MH; Mathew SJ; Murrough JW
    Am J Psychiatry; 2021 May; 178(5):437-446. PubMed ID: 33653118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).
    Pizzagalli DA; Smoski M; Ang YS; Whitton AE; Sanacora G; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu DV; Murrough JW; Yang H; Weiner RD; Calabrese JR; Goodman W; Potter WZ; Krystal AD
    Neuropsychopharmacology; 2020 Sep; 45(10):1656-1663. PubMed ID: 32544925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active versus sham DLPFC-NAc rTMS for depressed adolescents with anhedonia using resting-state functional magnetic resonance imaging (fMRI): a study protocol for a randomized placebo-controlled trial.
    Lv R; Cai M; Tang N; Shi Y; Zhang Y; Liu N; Han T; Zhang Y; Wang H
    Trials; 2024 Jan; 25(1):44. PubMed ID: 38218932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroconvulsive therapy effects on anhedonia and reward circuitry anatomy: A dimensional structural neuroimaging approach.
    Cano M; Lee E; Worthley A; Ellard K; Barbour T; Soriano-Mas C; Camprodon JA
    J Affect Disord; 2022 Sep; 313():243-250. PubMed ID: 35764228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study.
    Darrow SM; Pizzagalli DA; Smoski M; Mathew SJ; Nurnberger J; Lisanby SH; Iosifescu D; Murrough JW; Yang H; Weiner RD; Sanacora G; Keefe RSE; Song A; Goodman W; Whitton AE; Potter WZ; Krystal AD
    J Affect Disord; 2023 Oct; 339():584-592. PubMed ID: 37467805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study.
    Greenberg T; Chase HW; Almeida JR; Stiffler R; Zevallos CR; Aslam HA; Deckersbach T; Weyandt S; Cooper C; Toups M; Carmody T; Kurian B; Peltier S; Adams P; McInnis MG; Oquendo MA; McGrath PJ; Fava M; Weissman M; Parsey R; Trivedi MH; Phillips ML
    Am J Psychiatry; 2015 Sep; 172(9):881-91. PubMed ID: 26183698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of connectivity-directed transcranial magnetic stimulation on anticipatory anhedonia.
    Wang X; He K; Chen T; Shi B; Yang J; Geng W; Zhang L; Zhu C; Ji G; Tian Y; Bai T; Dong Y; Luo Y; Wang K; Yu F
    Depress Anxiety; 2021 Sep; 38(9):972-984. PubMed ID: 34157193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motivational deficits in effort-based decision making in individuals with subsyndromal depression, first-episode and remitted depression patients.
    Yang XH; Huang J; Zhu CY; Wang YF; Cheung EF; Chan RC; Xie GR
    Psychiatry Res; 2014 Dec; 220(3):874-82. PubMed ID: 25262638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Treatments for Anhedonia.
    Klein ME; Grice AB; Sheth S; Go M; Murrough JW
    Curr Top Behav Neurosci; 2022; 58():467-489. PubMed ID: 35507281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
    Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anhedonia as a central factor in depression: Neural mechanisms revealed from preclinical to clinical evidence.
    Wang S; Leri F; Rizvi SJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110289. PubMed ID: 33631251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling.
    Jacobson ML; Wulf HA; Tsuda MC; Browne CA; Lucki I
    Neuropharmacology; 2020 Oct; 177():108254. PubMed ID: 32726598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant reward dynamics in depression with anticipatory anhedonia.
    Guo Y; Huang X; Li Z; Li W; Shi B; Cui Y; Zhu C; Zhang L; Wang A; Wang K; Yu F
    Clin Neurophysiol; 2023 Oct; 154():34-42. PubMed ID: 37541075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.